With details on lead sialoglycan degrader in place, Palleon raises $100M series B 

Having nominated a lead program, identified top indications and sorted out manufacturing, Palleon raised a $100 million series B round to bring its enzymatic sialoglycan degrader to the clinic for cancer.

Palleon Pharmaceuticals Inc.’s central thesis is that certain sialylated glycoproteins act as immune checkpoints, and that modulating these siaologlycans or their receptors can tune immune function in cancer and autoimmunity...